Results 41 to 50 of about 760,353 (358)

Wilms\u27 Tumor and Neuroblastom: Results of Therapy [PDF]

open access: yes, 1973
Wilms\u27 tumor and neuroblastoma are numerically among the most common noncerebral malignant solid tumors in children.
Maurer, Harold M.
core   +1 more source

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

open access: yes, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A.   +4 more
core   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Identification of integrin drug targets for 17 solid tumor types. [PDF]

open access: yes, 2018
Integrins are contributors to remodeling of the extracellular matrix and cell migration. Integrins participate in the assembly of the actin cytoskeleton, regulate growth factor signaling pathways, cell proliferation, and control cell motility.
Arun, Adith S   +2 more
core   +1 more source

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer

open access: yesScientific Reports
This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase III clinical trial.
Natàlia Lorman-Carbó   +20 more
doaj   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

open access: yes, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G   +2 more
core   +1 more source

Evaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer ...
Natalie Waligorski   +9 more
wiley   +1 more source

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

open access: yes, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly   +9 more
core   +1 more source

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul   +13 more
wiley   +1 more source

Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

open access: yesMolecular Cancer
Summary Epigenetic modulators in combination with proapoptotic drugs have become the standard of care treatment in hematological malignancies. Conversely, these combinations have failed to demonstrate clinical efficacy in solid tumors.
Yaiza Senent   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy